Search Results - "Zhao, Fuxing"

Refine Results
  1. 1

    Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development by Shen, Guoshuang, Zheng, Fangchao, Ren, Dengfeng, Du, Feng, Dong, Qiuxia, Wang, Ziyi, Zhao, Fuxing, Ahmad, Raees, Zhao, Jiuda

    Published in Journal of hematology and oncology (19-09-2018)
    “…Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor…”
    Get full text
    Journal Article
  2. 2

    Optimization of glass spray tempering parameters based on response surface methodology and economic analysis by Liang, Tian, Liangliang, Wang, Fuxing, Zhao, Fengxiao, Liu

    Published in Applied thermal engineering (01-12-2024)
    “…•Experimental design of glass spray tempering using RSM.•A regression equation was obtained between particle count and each process parameter.•A regression…”
    Get full text
    Journal Article
  3. 3

    The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis by Huo, Xingfa, Li, Jinming, Zhao, Fuxing, Ren, Dengfeng, Ahmad, Raees, Yuan, Xinyue, Du, Feng, Zhao, Jiuda

    Published in BMC cancer (19-01-2021)
    “…The role of capecitabine in neoadjuvant and adjuvant chemotherapy for early-stage triple-negative breast cancer (TNBC) is highly controversial. Our…”
    Get full text
    Journal Article
  4. 4

    Genome-wide analysis of gibberellin-dioxygenases gene family and their responses to GA applications in maize by Ci, Jiabin, Wang, Xingyang, Wang, Qi, Zhao, Fuxing, Yang, Wei, Cui, Xueyu, Jiang, Liangyu, Ren, Xuejiao, Yang, Weiguang

    Published in PloS one (07-05-2021)
    “…Gibberellin-dioxygenases genes plays important roles in the regulating plant development. However, Gibberellin-dioxygenases genes are rarely reported in maize,…”
    Get full text
    Journal Article
  5. 5

    Development of Tumor Markers for Breast Cancer Immunotherapy by Fang, Qianqian, Shen, Guoshuang, Xie, Qiqi, Guan, Yumei, Liu, Xinlan, Ren, Dengfeng, Zhao, Fuxing, Liu, Zhilin, Ma, Fei, Zhao, Jiuda

    Published in Current molecular medicine (01-01-2024)
    “…Although breast cancer treatment has been developed remarkably in recent years, it remains the primary cause of death among women. Immune checkpoint blockade…”
    Get more information
    Journal Article
  6. 6

    Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis by Xin, Yuanfang, Shen, Guoshuang, Zheng, Yonghui, Guan, Yumei, Huo, Xingfa, Li, Jinming, Ren, Dengfeng, Zhao, Fuxing, Liu, Zhen, Li, Zitao, Zhao, Jiuda

    Published in BMC cancer (23-11-2021)
    “…Some studies have shown that Immune checkpoint inhibitors (ICIs) have a favorable efficacy in advanced triple negative breast cancer (TNBC) patients, but the…”
    Get full text
    Journal Article
  7. 7

    Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment by Shen, Guoshuang, Zhao, Fuxing, Huo, Xingfa, Ren, Dengfeng, Du, Feng, Zheng, Fangchao, Zhao, Jiuda

    Published in Frontiers in oncology (23-07-2021)
    “…Background This meta-analysis aimed to better elucidate the predictive value of human epidermal growth factor receptor 2 (HER2)-enriched subtype of…”
    Get full text
    Journal Article
  8. 8

    Elevated expression of TUBA1C in breast cancer predicts poor prognosis by Zhao, Yi, Wang, Wenwen, Li, Jinming, Du, Jiarui, Xie, Qiqi, Wang, Miaozhou, Liu, Zhen, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda, Shen, GuoShuang

    Published in PloS one (30-11-2023)
    “…α1C-tubulin ( TUBA1C ) is a member of the α-tubulin family and has served as a potential biomarker in a variety of cancers in many studies. In this study, the…”
    Get full text
    Journal Article
  9. 9

    Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis by Liu, Zhilin, Li, Jinming, Zhao, Fuxing, Ren, Dengfeng, Li, Zitao, Chen, Yongzhi, Huang, Shifen, Liu, Zhen, Zhao, Yi, Wang, Miaozhou, Li, Huihui, Xu, ZhengBo, Shen, Guoshuang, Zhao, Jiuda

    Published in BMC cancer (09-04-2024)
    “…Triple-negative breast cancer (TNBC) is a life-threatening subtype of breast cancer with limited treatment options. Therefore, this network meta-analysis (NMA)…”
    Get full text
    Journal Article
  10. 10

    Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis by Li, Jinming, Shen, Guoshuang, Wang, Miaozhou, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Zhao, Yi, Zhao, Jiuda

    Published in Clinical and experimental medicine (01-09-2023)
    “…Neoadjuvant treatment options for triple-negative breast cancer (TNBC) are abundant, but the efficacy of different combinations of treatment options remains…”
    Get full text
    Journal Article
  11. 11

    Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy by Zhao, Fuxing, Li, Enxi, Shen, Guoshuang, Dong, Qiuxia, Ren, Dengfeng, Wang, Miaozhou, Zhao, Yi, Liu, Zhen, Ma, Jinhua, Xie, Qiqi, Liu, Zhilin, Li, Zitao, Gao, Lihong, Zhao, Jiuda

    Published in Journal of gastroenterology (01-07-2023)
    “…Background Almost all adjuvant chemotherapy regimens for gastric cancer recommended by guidelines are fluorouracil (5-FU) based, and 5-FU-based adjuvant…”
    Get full text
    Journal Article
  12. 12

    Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis by Wang, Tianzhuo, Shen, Guoshuang, Li, Jinming, Huo, Xingfa, Wang, Miaozhou, Liu, Zhen, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

    Published in Current cancer drug targets (01-01-2023)
    “…The optimal second-line therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast…”
    Get more information
    Journal Article
  13. 13

    The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis by Tang, Yuyao, Shen, Guoshuang, Xin, Yuanfang, Li, Zhoujuan, Zheng, Yonghui, Wang, Miaozhou, Liu, Zhen, Zhao, Yi, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

    Published in Therapeutic advances in medical oncology (01-01-2023)
    “…Background: The use of antibody–drug conjugates for the treatment of advanced-stage human epidermal growth factor receptor 2 (HER2)-low expression in breast…”
    Get full text
    Journal Article
  14. 14

    Maize Ethylene Response Factor ZmERF061 Is Required for Resistance to Exserohilum turcicum by Zang, Zhenyuan, Wang, Zhen, Zhao, Fuxing, Yang, Wei, Ci, Jiabin, Ren, Xuejiao, Jiang, Liangyu, Yang, Weiguang

    Published in Frontiers in plant science (09-03-2021)
    “…Plants have evolved a series of sophisticated defense mechanisms to help them from harm. Ethylene Response Factor (ERF) plays pivotal roles in plant immune…”
    Get full text
    Journal Article
  15. 15

    Watson for oncology decision system for treatment consistency study in breast cancer by Liu, Yaobang, Huo, Xingfa, Li, Qi, Li, Yishuang, Shen, Guoshuang, Wang, Miaozhou, Ren, Dengfeng, Zhao, Fuxing, Liu, Zhen, Zhao, Jiuda, Liu, Xinlan

    Published in Clinical and experimental medicine (01-09-2023)
    “…The Watson for Oncology (WFO) decision system has been rolled out in many cancers. However, the consistency of treatment for breast cancer is still unclear in…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis by Huo, Xingfa, Shen, Guoshuang, Wang, Tianzhuo, Li, Jinming, Xie, Qiqi, Liu, Zhen, Wang, Miaozhou, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

    Published in Frontiers in oncology (20-02-2023)
    “…Many systemic treatment options are available for patients with human epidermal growth factor 2 (HER2)-positive breast cancer brain metastases. However, it is…”
    Get full text
    Journal Article
  18. 18

    A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis by Guo, Xinjian, Zhao, Fuxing, Ma, Xinfu, Shen, Guoshuang, Ren, Dengfeng, Zheng, Fangchao, Du, Feng, Wang, Ziyi, Ahmad, Raees, Yuan, Xinyue, Zhao, Junhui, Zhao, Jiuda

    Published in BMC cancer (20-11-2019)
    “…Chemotherapy can improve the survival of patients with advanced gastric cancer. However, whether triplet chemotherapy can further improve the survival of…”
    Get full text
    Journal Article
  19. 19

    Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis by Zheng, Yonghui, Shen, Guoshuang, Zhang, Chengrong, Huo, Xingfa, Xin, Yuanfang, Fang, Qianqian, Guan, Yumei, Zhao, Fuxing, Ren, Dengfeng, Liu, Zhen, Wang, Miaozhou, Zhao, Jiuda

    Published in Clinical and experimental medicine (01-11-2023)
    “…Anti-human epidermal growth factor receptor-2 (anti-HER2) therapy has shown excellent efficacy in patients with HER2 overexpression and amplification. Although…”
    Get full text
    Journal Article
  20. 20

    Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis by Shi, Mingqiang, Li, Zhoujuan, Shen, Guoshuang, Wang, Tianzhuo, Li, Jinming, Wang, Miaozhou, Liu, Zhen, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

    Published in Cancer pathogenesis and therapy (01-04-2024)
    “…Metastatic triple-negative breast cancer (mTNBC) is an aggressive histological subtype with poor prognosis. Several first-line treatments are currently…”
    Get full text
    Journal Article